PODD - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the First Quarter 2019 Insulet Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Deborah Gordon, Vice President, Investor Relations and Corporate Communications. begin. may you Ma'am,

Deborah R. Gordon

and IR Good website first thank year With quarter Petrovic, Executive are Lauren. and Vice available quarter us of Financial Chief me and XXXX this for for our Shacey Officer. Officer; Chief and our XXXX President McMillan, second be of XXXX release afternoon also press you, Executive you President and section quarter joining today Wayde archived Thank earnings will replay our the discussing full guidance website. results in is The on and call and our our first call.

actual forward in statements statement and no Harbor and to earnings obligation we release made in be in and risks may we the risks that like by results Before turn commentary call or stated, the with this different such forward and include to statements the over a materially during that on statements. company's change update Shacey. known future course percentage of unless looking changes certain forward-looking inherent would of note from unknown filings first with to uncertainties I such be by these Insulet be results quarter limitations actual Safe call statements cause uncertainties referenced in inform I'll results all begin, SEC. if assume may the even implied Please you involve Such our addition Also, the to any those the that to looking and regarding otherwise future expectations materially. financial will and And dollar year-over-year that, basis.

Shacey Petrovic

sustainable other we people for trajectory of execution out everyone. through Improving Thanks, quarter. a is innovative foundation the and progress innovation made diabetes Deb, with building great of first everything our XXXX we tremendous year the profitable continued and coming at and our growth. our which and of the during with and strong we long-term the lives strategic of In technology quarter afternoon, XXXX, of growth core do, was good imperatives

significant imperatives the and success strategic to transition us over profitability continued and our and Our for progress financial the near long-term. operational on position

product We are the U.S. were market highly to and pay-as-you-go fruition shift accomplishments revenue accelerating while direct of total quarter. of they the our to our our start-up automated benefit grew first growth full XX%. manufacturing, in the the U.S. model. coming operations fronts diabetes release, are XX% These of over Omnipod line DASH the many corresponding years driving on making including And the and a in with in major total Europe

market, for growth. and of mid-single To to total believe the users market. global for target insulin billion uniquely us successfully we revenue X into growth diabetes population. this market digit digits has Our Type daily our account of into users user the available rate move the of our Today, XXXX and we penetration Omnipod long percent requires achieve penetration to penetration low insulin confirms to injection dependent global dependent it Omnipod $X single runway Type given multiple lower are X converting even a low Insulet

the Type We grow people market, have our over to us first the year I'll for terrific the And further entered which financial our quarter. CFO helped official in into open XXXX growth, for as drive to the We're strength. delivery insulin system, and start Omnipod provide joins will a an turn DASH will a today's position Omnipod call diabetes highlights off call, with diabetes. Type results automated a global X X of further which Type our be who on Wayde Horizon of update details game multiple changer I'll then, expansion, and imperatives questions. call for innovation call guidance. in first having XXXX and Wayde, then, progress we'll Insulet. his share levers like the review provide financial to on us and both insulin On this X our to dependent strategic And from

and accomplishment I of highly Before this to Governor, future. commemorate provide what wonderful an State automated joined were Eldridge; highlights, our strategic important making I'll getting headquarters for keynote facility. Jamie and the We U.S. town ribbon day up few cover worldwide Charlie speaker, Massachusetts new This cutting around start Baker; the manufacturing the update new our we was Acton many financial held our exciting celebrating an saying by our Insulet's was of Insulet. country and our manufacturing running. Podders morning a morning, and officials; exciting officially on progress opening by ceremony lines In Senator It from a of and this employees. I'll dedicated minutes, we're our

million Moving And on a a and representing we year-over-year. We first and XX% one gross performance business to to strong year. to to our throughout the our margin our exceeding global approximately made in delivered to to $XXX expand in model and innovation, drive continues in XXXX Ensuring more We XX% revenue products improvement start important from to quarter the top ago. financial year our be imperatives excellence. the profitable market drove access, access accelerate QX summary, resulted progress quarter the have guidance strategic XXX-basis-point increase priority. to of our product footprint, a to people great quarter a advancing operational and another grow

Medicare one-third XXXX, of half greater of X an of quarter coverage lives. expanded million additional all for first Medicare coverage Medicaid bringing over beneficiaries all the and and Medicaid to During total lives we than our

established to that expanding ended And our DASH coverage approximately an covered for platform, XXXX we Cardinal the expanded the for with our and the just coverage distribution in QX covered million XXX recently million distribution complement pharmacy we of network. lives through Health, And to We wholesalers secured recently to lives. Omnipod XXX impressive secure pharmacy the one largest through country continue by DASH. of launched majority end also with the We channel.

continue pathway growth. ahead, innovation and channel market to that Looking we access sustained pharmacy provides model for the business believe expansion through a

launch broad position coverage of mainly with channel. our the pharmacy this leveraging through are We DASH

to have support. and advantages laser-focused placed the period wait driver competitive their We Our already pay-as-you-go have of key technology. DASH reduced but model the without have the does product now thousands States. to the Customers adopt cost as DASH have a not to to provides are know capable is get payers. having several business who feedback is technology lock-in upfront on we DASH removed so lock member and just a is pumps, has a commitment it the until for and expired. risk no of because we payer in patients seamless all cost that and people on DASH zero have upfront strategic terrific providers barriers been United new Unlike our technology insulin coverage, Omnipod there with and year our side, expanding of important pump four And we will pre-orders attrition clear differentiator us on cost DASH. terrific, as This can strong has performance exciting of new in for individuals to Omnipod will started. continue means Customer for customer to as also users. access as these and we in traditional be is insulin It patients, major and for adoption a well only like for

appeals automated simple. should During to significant ability required DASH, process our have These assist release experience the limited our as partners, be and critical resources online that And coverage. process efforts built the competencies, of for new the specialty through capability market we such who integration pharmacy already patients complex, time, and don't building. investments with was while customer ordering DASH

as and result we we position are to capabilities continue demand best product their the There our much model platform and a and is access these experience. customers we of next more great be a We have our generation investments, to business the for DASH look not As and to DASH innovation. build into forward to in patient mobile now benefiting launch will from ensure and delivering we market. customers, this the remarkable to stronger be excited enthusiasm could

As shown and predicted, DASH X insulin dependent Type the rates diabetes. Type satisfaction with living people high X among has market research

the basal with profile. to temp expressed in simplicity enthusiasm use segment the be of zero DASH's to pay-as-you-go customer Type system's the and people diabetes, believe easy unparalleled appealing living thanks X particular and X and fact, ease DASH set for and We upfront model its very Type discretion. CalorieKing insulin its dependent advantages In to food cost will pharmacy library and

best FDA the big if visibility, dependent than DASH States and population. believe as human expect further factor Type the As help not our penetrate we X can we like market, adoption insulin In least to the diabetes they concentrated to help insulin come in United U-XXX weeks. X and bigger insulin drive completed this innovations the the can diabetes is Type concentrated Omnipod you program and more study summative among U-XXX the this us submit have next few segment. to at We successfully where market, population

Omnipod make insulin roadmap with delivery progress Horizon We continue innovation automated important on system. our our to

further that supports winner patch by said as control. switch large closed will hybrid of insulin product. standalone even design and respondents with Seagrove ease system. to research our loop control biggest the a Horizon of Omnipod with glycemic single the game provides it delivery is pump recent Partners, system would smartphone and of making on-body market changing. best both use Our data to further a phone The personal an automated According percentage control embodiment they Horizon be

in Horizon in quarter are track work remain the market start our this and to great year of and technology We making year. second our pivotals on fourth half to bring progress with development next the of clinical

Horizon X range preschool also world data over our proud presence consumer be provide System. a will our report for include long from presentations the way examine a American use Omnipod Diabetes clinical abstracts control XX,XXX will We the Also month Association including in technology real clinical to ADA X. perspective, support term users, seven outcomes benefits next Omnipod to once meaningful ages and timing which have will glycemic clinical improved accepted. on of presentations at are customers. and again to leading from in show the with These large positive for leveraging innovation so we further outcomes children

focused perspective, iOS-based innovation effort we to algorithm approved source, an support by the development loop an app Tidepool's continue and getting from on Lastly, open FDA.

to for strong with insulin members additive this of the enable and investing a way empathize It advanced and And community's the and automated compelling Tidepool off-label. understand for to Omnipod market wonderful the condone be collaborating Omnipod we internal cannot we DIY while of to indication this support off-label use, an market supporting Tidepool who the urgency technology is precisely so as have technology. a component the why it program of possible. is community community understand strong and demand we program and using loop are to desire are We FDA-approved a delivery Horizon is are This our Horizon significantly system. get to as Loop significant technology. desire We certainly to already sense is quickly of

we our addition efforts, also in footprint. innovation In investing are to our global

in in been team months has done and capabilities European now Insulet's for model place has direct building and job our in an XX our reputation Europe markets. incredible Our

our testament of the drive taking serve, positively we in in strong preferences a are seen to operational European reflected Promoter are into markets And are Net we the our have direct our now Score. already operations, meaningful seeing increase commercialization user team. Promoter strength Since that we and this to We market-leading sizeable best-in-class that Score, Net performance. help insights a gaining innovation, and to the closer customers already will we over

capabilities others made advocacy, a We have functions. international regulatory, our to including market distribution customer build and significant European-based our support investment access, among

deeper very markets now drive to our geographies existing are opportunities We for and growth. ultimately new to expand into well see into tremendous where we positioned

from are successfully focus opportunities to during opportunities our expanding part the are just value presence. we our to the we global in interest on significant have markets those markets in We we in on enthusiastic a expansion strategic the are there to of international existing thoughtful a XXXX and currently know to executing footprint and expanding as continue to Omnipod strategy our strategy. in in available then evaluating is outside intend Europe, long-term XXXX. United Building States shift handful countries is we numerous There of and

We throughout have accelerated globe. for growth the catalysts multiple and expansion

rapidly for in the Lastly, meet on growing foundation I our operational to demand. excellence our want in manufacturing lay China, which, addition touch our operations and in the to capabilities a ability to U.S.

Over highly and the manufacturing. next two to our we that cost producing This XX% am validates two to provides all custom our for report our reduction. line last will expectation U.S. thrilled with chain up facility successfully so experience our XX% U.S. have begun we that early years of the will I automated capacity designed our in over of the years to or up automation China at one invested have new Omnipod produce lines less further in of redundancy U.S. drive head supply count. in and sophisticated

are on this our track our to support rapid second year We Massachusetts further growth. our later which in install will line facility

greater to position industry. plays Wayde this continued driving of With cementing a key value our detail. leader I financials turn while in to in a in margin that, will All and over creation, the the Insulet's role expansion discuss call as global

Wayde McMillan

Shacey. you, Thank

take like exciting turn and with Before of initial Insulet speak to CFO a to you I I'd as share the evolution delighted in the moment am to this at to to say couple a how company's financials, I moment observations.

First, level lives with all clear and of every organization. we at the the people employees in heart have the improving is the do, passion diabetes at of it's for that exists our

making products. a in difference real the of our those use lives are We who

have capitalize market old continuing Second, technology working to-date here significant of we have in is front the model we which The and the opportunities significant with I to market and differentiation is the look Insulet pay-as-you-go disrupting us. in advantages and forward with impressive, with progress pharmacy, our team at to paradigms. on the

end million million, Now million of end was $X.X above quarter results, which total to $XX.X to high quarter as of delivered grew revenue product on strong above growth we our another performance $X.X representing our to financial was mentioned, $XX of guidance Omnipod million revenue range million line, our range, guidance of achieving of revenue By our end first and of Omnipod $XXX of with high U.S. or of range. our XX% Drug revenue grew the Shacey $XXX.X $XXX of International our XX% represented XX% our $XX.X which the million. Delivery month was million million, delivering guidance high overachievement. order majority last $XX.X $X.X which the million total was end in guidance high from the largest the And resulting an the increased of above expectations from growth, XX% million customer of quarter. the

expectations. as XXX expansion successful we basis supply significant margin, in purchasing, line gross from expansion to realize resulted chain drove Turning once direct continue as cost and This improvements again incremental in points and in reaching our last to of XX.X%, the operations. our with considerable productivity year, operations manufacturing up well and benefit we our transition to Europe

we million to trajectory representing our of investments the last expenditures line to U.S. year. on planned invest we at our ended and cash operations. first in in of of growth driven our ended with financial XXXX quarter capital seeing were out year and continue by was that summary, X.X% another representing This cash the quarter were expenses continue chain coming operating for and with profitability. supply QX million revenue. momentum of Our the as $XXX manufacturing million primarily operating million revenue of well-positioned in performance. and feel and $X.X We We strong a In $XXX and net expectations income with of of compared growth we're use $X.X income X.X% in of we end

on Next, provide update XXXX I'll guidance. an our

of or XX%. XX%. to XX% line, up range previous $XXX now representing $XXX revenue first $XXX Omnipod full million million of our of XX% of This million, to growth As million, XX% guidance. XX%. expect to total expectation $XXX we're million the result raising of in to $XXX XXXX million we $XXX our to $XXX raising year, U.S. product to XX% a By revenue performance, expectation for growth or to compares to million revenue our to previous from to XX%, $XXX our of of quarter total are our the million, growth representing We range

of million, now representing to is to of International For the unchanged. million XX%, $XXX growth range we expect $XXX XX% Omnipod, in revenue which

for continue We strengthen our markets. on opportunity capitalize our in our growth capabilities and existing to

in the a result, direct and half growth half as Europe strategy to reminder, this of in will As revenue of we go we the first year, as compared have higher our a launched year. last second in year, last

We a more growth to expect continue our existing in low second to rate XX% markets. normalized half of mid-teens

revenue decline. overachievement, raising based XX% to to quarter Delivery, Drug for our $XX Lastly, to first million we're XX% on $XX our representing million, range an

million, total XX% $XXX of $XXX to million, are of For million growth growth to to Omnipod introducing $XX the includes representing we second $XX to This revenue representing revenue XX% XX%. guidance quarter, million of XX%. U.S. of

pay-as-you-go reminder, in our first are As with in of well launch in both the time the to full model product in as some as for in of A new business market is is our through a temporary QX, capabilities, release no-charge we shift in and our the working systems, a DASH pay-as-you-go Omnipod U.S., our revenue which requires presents pharmacy, the key new component differentiated processes. included which and QX significant the all model headwind guidance. PDM,

distribution a to XX%. last And of Omnipod transitioned negative as converting former $XX Drug of decline favorable International expect impact million, our comprised well of representing the an Delivery of as to distributor. last business, QX our in now comparison European in representing a from to approximate revenue revenue European that $XX to of quarter XX% we our growth XXX% uplift we year, $XX operations, channel to last, from we have to direct million, in revenue This XX% million expect incremental growth million benefit benefit We is the reflects of XXX%. Europe. of direct in $XX This from as

rest guidance unchanged. the P&L, of remains our For the

gross full-year of with partial the benefit temporary from in reflecting to XXXX continued our model headwinds changing will the and our chain Europe QX offset supply improvements, of relatively ramp, be with sequentially margin, U.S. our margin a manufacturing. gross our U.S. impact expect that we last by consistent expect lower. and business quarter Therefore, of We year, operating manufacturing be ramp

the second of of due manufacturing. QX, be expect lower also than year margin ramp the to U.S. gross We half to continued

For of due our expect and to pipeline, XX% a relatively operating investments increase innovation in approximately as revenue. we to to remain expenses, consistent continued percentage

our range, margin as operating percentage full-year deliver to drive expansion relatively and summary, and U.S. contributions expect long be In growth to of with margin in expect our and to the first started continue invest year manufacturing we cost capital delivering over to in a quarter consistent indicator profitability, XXXX, the reductions, of we redundancy, mid-single-digit the We term. of the revenue execution sound expenditures to we an strategy. strong

Given deliver operating believe that margin gross revenue, and solid and financial are for well-positioned and momentum, growth positive to XXXX, our on profitability we XX%, in our of margin we mid-teens. billion the $X of goals in remain track XXXX foundation throughout continued and

the call Shacey. to back Now, I'll turn

Shacey Petrovic

to while on for line investing driving I ahead Thanks, we on Wayde's great as Insulet, like our the you excellence focused and opportunities have and growing excitement in about execute international to growth. team. Wayde. reiterate footprint, all innovation, would It's and expanding and top our market, build strategic on bottom demonstrating to the significant are we continue our imperatives, addressable momentum operational our

superior value shareholder for roadmap confident in long-term we growth which performance, creation. place significant financial have will drive right and the We are

like to for the to turn call back I'd open the operator Now, to questions.

Operator

Thank you.

McKim comes question with JP from Jaffray. Piper first Our

Your open. line is

JP McKim

QX, acceleration market with way the there? XX to talk or could Shacey, adding to the Thank I for innings release lumpy – And from or costs, and lives it, want Good the adds, did or way pharmacy. that can you I in to quarter, just don't about demand you a new the first million qualitatively right you taking given afternoon. your limited any but maybe, did wanted see that? to early the think it see then, Hi. be here start Is quantify questions. like low that of that in upfront patients, say you

Shacey Petrovic

Sure. Yeah.

assume in plans terms There still lumpy. access, I working of few are there be to could it's DASH we're going think that So large somewhat out a you on.

those that we will adds, So the to build throughout could access be year. continue and significant

but So position we – XXX a lives. It's coverage strong covered to DASH. million about feel move for great really having into

So that's great.

adoption on of PDM, a kind no-charge and experience with terms that. the of of at In the we're color where couple early about pieces just customer

The terms first record is that of QX another quarter for us was starts. in patient new

of delay. right? moved good full soon end about thing in for the release that's the great they the we to great then of a that in able strength our that the just that no pipeline, business to model, the full DASH. release now, feel think innings product And Omnipod, in promotion, market access thousands a And haven't we of spot. we're my to in to this have market Because full we're that to the technology with the already really any they'll market early DASH, But so for that channel, slowdown they like I we're to starting on into got is testament we've said QX preordered promotion remarks, we people have DASH. supply prepared neared as as demand a as of ramp type the And and I without of get as at know so patients can and release be kind access we of any seen

JP McKim

first? Like, or for and you approved example, Loop's so Loop first Loop already one Horizon That's a just helpful. closed-loop trial, gets to with their for Horizon do second, could And on is something could launch Loop? and started you'd then on your system there and have ask I end if Horizon,

Shacey Petrovic

kind to one see were of to potentially programs. market we get they reasons their reasons to to agree capitalize value are makes I strategy, in the one first, to but prepared pathway do Tidepool, to – both of partner faster on product that the they and FDA a able if – and clinical of to it so whichever we We market, many there was were had with mean, Yeah. the reasons

JP McKim

Thank Okay. you.

Shacey Petrovic

JP. Sure. Thanks,

Operator

Our next David question comes Stanley. Lewis with from Morgan

Your line is open.

David Ryan Lewis

quarter, Congrats got on company, glad got alive. I'm just here couple the anyway, the a me welcome. out that business. just But you for Great. other quick on Wayde, questions U.S. and, out of

Shacey, second quarter, DASH. you'd for from initially, you thought discussed the So a and see you headwind pharmacy

$X year, said sort for million of on but guide, actually the to quarter stable $X I look you the think million at pretty it's basis. second I momentum and

So to year, I'm just to demand or see the quarter? or headwind more million for and of still be of better million specifically, sort seeing second underlying $X wondering, is $X could you pressure that headwind, you what the quarter, of are the offset helping a you in less the in just sort that second

Wayde McMillan

Thank we It's PDM. PDM estimate the million the hey, where Yeah, which here. so we the quarter, million are be revenue of about to in David. from for the no-charge model, because thanks $X expecting is year have last and still Yeah, to this holding pay-as-you-go of unfavorable you, a great comment. $X

PDM; words, will recognized this the So in we year, other not. we year last revenue for

For some the of model, sold will no-charge our but PDM. those traditional PDM channels, under are sales, pay-as-you-go it some that still for the be be a through will

so $X was that said million. be What And be it neutral million the for year. to still think will we also $X will it we

moving for no-charge (sic) start start offset and we will And will customer and PDMs, as of model, to so And that will benefit we of us. what that will the model, means to QX here base and pay-as-you-go in the no-charge channel pharmacy start will the have our eventually start those that builds, to ramp. ramp is, become as benefit accrue. a into customers tailwind The

will have so the for our good the PDM, that upfront business, will the term, favorable of over headwind because long more for it us. be on a And from pay-as-you-go customers we'll we overall model, a the that get but more be impact

So answers question, the that David. hopefully

David Ryan Lewis

Can update, for assuming sounds just the And Shacey, for a I'll is clearance, in that Thanks be estimate? much. just momentum of timelines kind for quarter, to the decent full be Horizon, of quarter And underlying second ask sort XXXX is U-XXX your commercial going is a the stable. second we or so it of like a demand half U-XXX Horizon. (XX:XX:XX), of half And about second reiterate XXXX then Okay. kind then you a as better think launch first in launch so XXXX? little commercial that a my scaled we're second for must around

Shacey Petrovic

great are Those questions. Sure.

your first a the comment, on the look sign business all, about we strength of as I and U.S. really the you can in the the U.S. think bump at of in guidance momentum first that feel in So good

concur would you I So that. on with

As a U-XXX, there, FDA impact terms in not it a we estimate really a it's more have bit to aggressive little – David, probably because revenue potential it relates material perspective, clearance of it's pretty I so niche matters, but from don't think population. a

standpoint. how release study more do to to was market And won't excited market of really from that evaluating now, use release actually are the test revenue and full last some limited things quickly. way get question We about clinical a then release. would normal about the it move but do market We're the to to get the needle potentially the offer being we able a to as actually market, product we full to a Horizon that the in

we'll kind you studies. color on pivotal So, closer give of that the and more the date we through as get FDA to approval

Operator

Thank you.

from next Our Jeff question with Johnson Baird. comes

is line open. Your

Jeffrey D. Johnson

website to more mechanics well. I'm rumor seem guess had into Good just well; website as as your on morning. DASH for on little I moved been it exactly about hearing like verbiage the that, how on but that sure Shacey, the DASH I DME that would of not you. but we've does apologize a focus work, some Thank DASH, there's DME

XXX driven if think it the from a million of is, differently we to from any than relationship? conceptually, that increase table, any our is that by So DME, just XXX lives side of and do have to about pharmacy-based million

Shacey Petrovic

don't. asked an overlap, DASH, in cases, glad not just I'm advantages at in Hey, and I they gives look opportunity some they're sort to us because – that We you and two it clarify. cases, think question, some actually, they to of

advantage hurdles, and it's the channel attractive attractive for easy pharmacy is a us, our channel. one patients, efficient, for that's and for financially it's really physicians, us, channel experience there's for and less patients, So, for customer attractive an good channel really a because channel, attractive a more it's

perfectly channel. And move the the and strategy the to can channel. apply – sort into it think channel, DASH separate, to of so we to the also really apply using is DME somewhat are pay-as-you-go we but could it pharmacy applies pharmacy But really

would into have and you're think to we So, a – transfer provider just already value willing United model, indicate Pod of the with we our the these I partner of to PDM website and on I willing contract provider are then if – them. if pay-as-you-go one certainly disclosed referring this move is DME to with verbiage the and them think that is the that DME a to

available So, yes, in channels. both be it will

However, today, are the vast lives United is the pharmacy. of and already had majority the pharmacy additional because majority secured vast we of that

Jeffrey D. Johnson

a to that DASH. out assume skin pharmacy patients it, interest would business I much right. that. the they maybe Wouldn't there's be All prefer want looking DME I to have be pharmacy guys That's but is for their I being DME able physicians as a this assume if assume to helpful. so mean, lose it, is better secular guess easier, for interested probably providers, And not in follow-up model? a you if would offer to prefer and that, pharmacy, own pharmacy a to a vested move I'd I towards doing and question going that the just in prefer for

Shacey Petrovic

who example we'll I for good that we're that, in and B designated plays other it's mean, providers. as think there's a I United great pharmacy, product to put so the payer Part see of but obviously is the how a reasons DME a did a product, question out.

feel is we what think is I growing. the that good strong and coverage about

And so and be is that, both pharmacy, to us. just earlier, to really able are indicator to as for strong a good we're Wayde business of which, us, that going primarily said just the transition in the really pay-as-you-go to

going a in the business the we'd the the me, pay-as-you-go So, of model, world, perfect vast and in have majority through pharmacy. secondarily, to

Jeffrey D. Johnson

you. Thank enough. Fair

Shacey Petrovic

Thanks.

Operator

with Margaret comes Kaczor William question next Our Blair. from

open. Your line is

Brandon Vazquez

on focus a the I wanted Congrats and and of Margaret. good on first DASH coverage. for pharmacy on to good just Brandon to quarter is This start everyone. kind the Hi, year.

You million the with one, just within clarify, far expectations how is Medicare/Medicaid? coverage covered And commercial pharmacy channel and breakdown then, mentioned the the you tracking that into between year? the now. two, Can so there's then lives your XXX just

Shacey Petrovic

Yeah.

detail point, So of Medicaid, and but Medicare, would slightly ahead the we at breakdown, at terms in share of this And don't that expectations or will we're commercial. tracking say our a in say I terms of it's of combination coverage. I

thing the to great like launching XXX% the good And just for we So is through everybody if opportunity the we just because in it's always I to percentage, to think a that take I really feel may a XX% be to position they remind it, larger were about that. us existing would lock-in in, period. to and but four-year contracts, it, call DME leveraging be channel, convert of stuck people our able – that would we be access all have

percentage small DASH to a of until them warranty only access out so waited would be And really, period. they their able

we and for long-term new somewhat establish as kind product, advantage like for that also the this, a channel this disruption said, business. new worth and tailwind disruption, because investment we're competitive we of these the contracts guess, do I So the is a model, and new as Wayde establish us causing feel and and this this great

Brandon Vazquez

been like with a and said, maybe especially recently. But advanced high-single-digits growth you features, of that and higher market. the that's are pump some seems it Got of looks taking kind makes other a And competitors, helpful just accelerating their view I market historically think probably as the sense. that to like it of the that, it. maybe market, follow-up has a like growing No, like

the do seems we patients have you getting lot of and go like come views accelerating, the do market, into any sidelines. updated it on guys anticipate As XXXX, are It year? accelerating companies through off this it the MDI you is a

Shacey Petrovic

that of Yeah. it's our still the Well, daily from injections. business it's true multiple majority, today vast comes XX%

better it's at testament have think people, grow it's the between And rates. especially getting pump market. and does is to I on somewhere does CGM, that great I difficult like estimates historic accelerating. higher adopting technology to helping you're and are like the right certainly overall grow is And that to just it data would X% get X%, technology I fact that, accelerating. are were feel – it it that with feel would that we a the just and So don't but it's say market

Brandon Vazquez

Thank you.

Operator

with comes Our Marcus Robbie from next question JPMorgan.

Your line is open.

Robbie Marcus

Great. entries happening Thanks how what's market for share the in do sense And the me, with because over but have guidance, options around considering about next taking can the your in for XXXX, first, few the not of more trajectory, is comfortable the Drug get for and there Two other Drug this to question. generic biosimilars? moving you we here? us you and potential think how a maybe help you years, any Delivery Delivery just get

Shacey Petrovic

Sure.

both So are guess, tied Drug to I Delivery. questions,

So term of trajectory to trajectory regardless example, of exploratory be Drug the goals, in what like, continue whatever give of – area. programs in stated – area early that of the it's offset we great long, going and in business are revenue tied things an levers really to to on our or look that for lot component of our business, there might so not obviously – we long-term Drug help risk to to a business, in activity plenty that for we benefit growth but on, XXXX comfortable the we our have said, development both feel margin Delivery. color do become terms those expansion trajectory because because think we are goals, That the a Drug meet continue international Delivery of of a long of Delivery I so the kind because happens smaller it's it's there with work

for of color an for it's specific have don't to we offer, So, us. still except exploration that area

Robbie Marcus

you as Horizon, that your great. could to look development see follow-up, XXXX, timelines the will for and we'll then like, product the when coming will what actually the Thanks. Okay, maybe of pivotal just was I UXXX what timelines. on hoping trial of late version submit, you'll pathway, the when And a market be just results, in lay latest us some out thoughts the on remaining

Shacey Petrovic

Sure.

milestone and have look we next data get probably That months that to in submit. update pivotal is everybody I UXXX. trial terms will take to for the pivotal. don't needs a on of then Horizon, few us that will through, consolidate So But and the an

I Program. think the that you do of call, Robbie, on many Breakthrough as Devices we know, were part designated the as

And interaction very so a very we with the FDA. have frequent collaborative,

So protocols, basis. regular our they strategy review on clinical milestones a they review and our our

that an result designation. as So process accelerated review from to a we expect of benefit

more XXXX. So we provide that milestones go you will and of to beyond of at this the data fact have don't early end those then And likely that consolidate the happen part will and submit. I pivotals year, the will through

I use after as of that how think market launch opportunities trial evaluating we the the was of that, In I are terms a earlier, able somewhat release. to out mentioning pivotal play limited might be to

of some the on strategy the pricing access that working through. And that kind we're and on all will strategy depend of

those continue submitting So a updates. pivotals, we'll yet, lot for certainly to you we I provide don't as color to to but offer have closer get of

Robbie Marcus

of a expecting just And that a back Thanks a is XXXX, different to now? we're the timeline lastly lot. launch here, half or still confirm in

Shacey Petrovic

there. timeline. that's the changes same no, Yeah, No

Operator

Leerink. question next with Danielle comes Antalffy Our from SVB

Your line open. is

Danielle Antalffy

and earnings a would very Thanks Hey. been say, question so that. taking for on for a It's the clean good, Thank Good I season. congrats afternoon, you guys. quarter. and much really tough

in more you what feels well? today percentage time question can as get could over prepared David's where a is you the Type talked market think much installed to market, of growing of to base on that And X once know I market. Shacey, up do commentary insulins we just be Type about you first, the the talk on that It X? concentrated remarks, U-XXX bigger your how are, UXXX follow that is a on the like could So, about – about mentioned niche we you

Shacey Petrovic

Thanks, Sure. Danielle. Yeah.

I that we X really without that about population. grow. us that to that's helpful, concentrated insulin-dependent what segment to think think reaction grow, but seen it got of we've believe with frankly, for We segment's and of insulins the way to that we've is continue are user going Concentrated believe a to in is to insulins. the terms Type or DASH, going was market pathway reacting experience, data XX% the tremendous. business our expand actually how why of they was about to It's just limited approximately and is we good of were got to it XX% today, the sort and too, which to visibility nice U.S. that DASH release, it DASH

insulin-dependent to feel X appealing both Type living really going very diabetes. So with product people a we also that's that and we be X good have to Type

have the larger right, people that because that, we've is you're of larger X, there UXXX is think with XX% grow Omnipod I think insulin without in but reducing contribute concentrated what could more, So and that total Type seen we fact, is much in opportunity dose opportunity by in insulins. living even daily actually business a just I almost to

Danielle Antalffy

And...

Shacey Petrovic

U-XXX and for we to grow are but UXXX, them we forward wait won't that looking So to business.

Danielle Antalffy

there insulin you actually any pharmacy about to as to knock that doing market? help to a the is that, talk access Type the how mean, could coverage barriers I perspective, from does pumps, for on knock are need move what just down? you X you're those there and And follow-up you insulin-dependent the down

Shacey Petrovic

Yeah.

appreciate news. X the the diabetes, channel. the that likely actually to with So of the great in I barriers non-existent much because lower to DME that's pharmacy why And for alluded that reasons actual particularly Type it's channel, that coverage, living segment the really relative are people to or one fact fact the insulin-dependent will

not channel. requirement in requirement is is So D one and DME the C-peptide Medicare channel which is the the a a pharmacy in Medicare just example test, Part

daily a one who Type – require people for actually good kind basis, that out just of really not pharmacy a of So, who in is great It's strong the all of we're people feel on channel coverage the Xs. benefits strategic position. we insulin the building

Operator

Thank with Raymond you. James. comes And our Jayson from Bedford next question

open. is line Your

Jayson Bedford

afternoon. Good

the Just every with of gets does a this user DASH, mean new ones that me, couple for release full DASH? quick logistically, market

Shacey Petrovic

Well, it's access-dependent.

lives. XXX So has every that it. wants can obviously, new But and covered get it million we've access user got

So XX% lives. that's of covered about XX%, all

have will patients would the access DASH. I that of that's to segment, new about And guess, so

Jayson Bedford

just in the the Okay. Cardinal with the all? mentioned fair. in stocking channel? as there like guidance XQ implied doesn't at That's just but DASH. orders to distribution guidance, you are It securing launch that then seem And you secondly, contemplated Is fill this

Wayde McMillan

Jayson. Hi, Yeah.

So working we're channel expecting in significant amount a QX. teams with right – through this not build of with our now,

However, very it monitoring is something closely. we're

So, we're sure be to teams with let we you if work not as And it, know. to channel. and we'll the through in new working see we QX, do this understand it

Operator

Berenberg with Thank next our And Misra from question Ravi Capital. comes you.

open. is line Your

Ravi Misra

Hi. taking the Thanks for question.

pull-through, So versus just this one follow-up. have a I then on DME and patient the of pharma kind

what have to the the I'm pump just your to of So, that Any coming more MDI appreciated. way? easier now is exposure it newbie, – patient coming as you're kind it more getting curious, is that be channel, of kind existing detail who Is access would this have or there pharma is and they users an off to it? way warranty and come

Shacey Petrovic

kind I don't front great color that have to a It's a the actually, of patient me. to will of you hasn't – level, I question. say offer Ravi, changed. I'd mix in high that And at

versus the XX% don't versus number MDI, patients patients us from daily in have a still of pumps our of about today, pumps. injections multiple coming change to we So come from

Ravi Misra

of we that you. is the on do and that, kind follow-up of making technology. is, through of easier Thank Okay. just in to in my the have just some in expectations G&A that, receive How the ordering, the that kind factoring we how of future? going do plays then DASH of And sounds with saw like seeing that any the we forward? obviously of playing And for P&L, you are patient leverage how it's that out in that think quarter, it kind the the was then

Shacey Petrovic

in quickly weigh on the I'll the Wayde – let and answer just I'd second. Sure. first,

to the DME. in plan in we pumps the that relative the So have don't the change expectations coming patients versus will from pharmacy of MDI mix

expect users. our fully to to stick which to we MDI convert So is with continue strategy,

Wayde McMillan

No, thanks, yet. question on not so the and of leverage,

the and the have able to other businesses. our in invest direct being we pharmacy is new to investment move the the while channel, DME we So, of support one had kept things into that for

the the And we and investment on that efficient the model, so side we as do expect the efficiently business to be over traditional time, more on given ramp more able scale, we'll that of does have a but it's given reduce but and time, impact base in the won't some channels. for an the to still that side, that have our probably see we traditional pharmacy on quarter, we business certainly not current support

Operator

from comes UBS. The you. next Matt Taylor Thank with question

Your open. line is

Matthew Taylor

Thank taking you for Hi. the question.

by could through about are help So, any like and if in quantify I I how the – if of with or simple relatively or impacted access first something channels? is how the trying Medicare was that us patients you lot last of those has wondering has expansion to some question, your the or you percentage of you one a Medicare, And ask just your the wanted talked that Medicaid was some course year a coming results, to expanded what could access provide over of color commercial.

Shacey Petrovic

start direct three have a say of we access. only impact calls I to – that, have now. I that specific running And result think running don't is new to numbers market have that had three now calls quarters provide, the I patients or think said four of record I

have see and also age group more likely certainly retention. we for in age so more And contribute starts started Medicare significantly significantly the to to and group example increase our to new patient

starts. but definitely it is percentage patient what of outsized in sense driving is a have don't I So it new performance contributing,

Matthew Taylor

the here wanted And about of follow on questions then just up Okay. DASH. I some to

loss I air thing have pocket. there's that may about an think to PDM is are the some that concerned cause you if one investors

I the to about or quarter how control through if by and million hit thought pacing have patients And to how of how on the it the to your you wondering try second talk to target go able it $X you've in which DASH the to be could you developing do over year. you promote release you about much was $X how guidance, us and million so

Wayde McMillan

Wayde. Matt. good. Okay, Hey, It's

from standpoint, $X to mentioned the we across million pretty it's as consistent the $X million we pacing the think So a year. before quarters of

in QX, than you total QX. important is the QX in think DASH I is of was know it small assuming into more the a revenue. QX is certainly know And our percentage release you to our it be revenue here, move know we're will that that we As and thing PDM

year if even range, that outside in the if we so, were be didn't words from And would move to significant. successful it wouldn't customers of but any probably have and our other headwind be revenue model, PDM the it we slightly guidance last pay-as-you-go all had

It's a in captured pay-as-you-go And that down the from customers right XX%. annual bit QX. the neutral to rate And we run and the reasons benefit so, accrue prior think us. our we we the ticked year becomes think of little for guidance model one the amount for from we at why tailwind a it's becomes and it we've once from more start eventually get on that, our

I – of don't I and revenue that So deal it's think of small out make just our would a so pretty huge overall. given percentage that a

Operator

Thank you.

with Our comes next Securities. Suraj from Kalia question Northland

is Your Suraj's has like line line open. disconnected. looks it And

with question next comes Doug from Our Schenkel Cowen.

line You is open.

Ryan Blicker

another taking record you in Hi. Doug. starts back mentioned my This patient for starts, to Maybe is Ryan for Thanks just of quarter new on the coming U.S. questions.

QX across did or record for be an does historical new any quarter added absolute that more you any specifically record QX to in mean QX? in Just patients you clear, a meaning than

Shacey Petrovic

QX. historical for any clarifying Yeah. for you record Thank a It's Great. that.

Ryan Blicker

typical new the if acceleration it pretty overall revenues, the seasonal trying patient and that to Okay, be to case. to just fair historically is in that that have a historically your adds would is in clear impressive been the make that because assume U.S., typically U.S.

Shacey Petrovic

Yeah, right. that's

true quarter. QX actually did have a is we So, lightest but bit, our stronger seasonally QX is a by it quite that

Operator

comes the with And question Northland next you. Suraj Thank Kalia Securities. from

Your line is open.

Suraj Kalia

hear guys you right? all me Can

Shacey Petrovic

you. got Yes,

Suraj Kalia

That's perfect.

somebody a placements. a I'm on let's I I forgive calls tactical say but least already look if at trajectory basis me it and forward-looking (XX:XX:XX) pumps. some on earnings a insulin Tandem from multiple color essentially if tactical a and companies Insulet Shacey, its and are Medtronic can heard on perspective, a curious all pump you market strategic really these does shed at on has ground? amount Tandem ground forgive understand some shift. lunar questions. on on we curious, be asked – there overall can answer the Obviously, to the us is combat now, hand-to-hand also is you the to give When I'm going about So, basis. how me tremendous something has this something color the putting versus of in appreciated. basis seems choosing R&D decision be comes there effort. tactical versus Tandem process Suraj XXXG more between in, But he how would Omnipod, if the a is anything greatly how on so, t:slim your work,

Shacey Petrovic

Sure, Suraj.

think I fair it's question. a So,

them So, driving, of difficult right. take different, supported not piece the that big hear differentiated I It's of we we therapy pump business not integration to models so we're XX% of quarterly adopted or are we're and CGM a they I got us I they tube and if otherwise so users, of from and basis rates where trajectory new to want that to very, think what's kind Tandem's move this understand don't pump also get tube growth now make say would is Horizon. clinicians a revenue data very of all for excited growth want growth who – also by the by just challenging kind on on that would first not pump, to challenging we a because MDI model, a way years DASH, CGM recurring of starts guess, Omnipod tell I'll so light what the those is patient is compare clear, They that's have our But example, revenue to which and gives it's the why four and about compare upfront be who Omnipod. which we've sure is what integration that for for rates.

are as they Horizon CGM segments all acknowledge strategic that So we're adopt out period, be that new to they to us overall kind move people now if like think why relates will reasons market said, grow business and these enable the to patients because that That of it's distinct so to was like we and to one too up really and bring enable they to curve integration to it four-year the able helping for the without Horizon coming want really innovation shift their we model innovations those want wait we like we of having we're I to. on believe the population. and should when to of as DASH technologies as kind DASH our do

invest important enables are drive the both bring us innovation to and also bring as market. this innovation to growth innovation to cadence that business to in to we to So move market us, continue that model at we

Suraj Kalia

Shacey. moving perspective. curious payment of get your I'd sum upfront of And my thank piqued question. made with marketplace? to I'll curiosity. taking to payers, Have be Thanks one you and it Essentially the model comments were discussions away get in sensed our the whole enough, you model. and be some my Fair question. my clinicians, on guys this monthly discussions keep taking In seemed follow-up of for Shacey, a couple for lump that very of towards any some there that

Shacey Petrovic

really I access is, the we're demonstrated DASH, for mean model. building Sure, are the answer it's clearly in why payers Suraj. attracted because to it's And yes quickly pay-as-you-go so

about of just same they're that pay-as-you-go flunking and they a that So, adjusted Both month down talked they compliance. I main you you call one outside risk hoping this right. because fee that the model. are piece payer. really eliminates just call for member the then the are And patient thousands that that Omnipod, moved it's are that kind not other in innovation reasons to dollars upfront, the risk payer and models we of per of It that for for or per of

Operator

you. Thank

Our with comes Markets. Wuensch BMO Joanne next question from Capital

Your line is open.

Steven Plachtyna

control maybe Steve the us Thanks you will markets, for in phone in toward maybe and as is just this Europe, internationally? Can hints update same feature have DASH this set which U.S. general question. on on Hi, any DASH taking for timing, the the Joanne.

Shacey Petrovic

great Yeah, a it's question, Steve.

of right reason We in so and So, our only we're of into a to all DASH go-to-market business we well so can we into business to wanted team right we months and plan that the that way mix brought the any make whole we the And do theses substantive understand new were products other presence what's plan that the to and XX DASH there, sure before into because bring of the is established various one was Europe. in do Europe. until and don't really to better XXXX functions for the configuration going the strategy markets because these in direct to Europe establish Europe. in

do is apps, we requirements privacy U.S. will know that be and configurations into different and value translations and with should we're where by tied year, XXXX. the sometime that. this and with to doing so we and great work of plan we'll and we what there's the go But are We slightly for demand. One the in see frankly different our market the DASH the data this that be propositions end early market in to tied there finalized to configuration product plan know is example we what the So, look also releases to may is than the launch see moving limited different have different and year

Steven Plachtyna

Okay. approval just Horizon with Great. the designation? to for then on have views pump FDA do could give your That's your very ACE ACE you here, And submit evolved helpful. you designation. plans us an Has latest thinking

Shacey Petrovic

do advantage of we pathway. we'll believe taking that Yeah, be

we'll at there's not clinical And point has and it's to yet tied no so, iCGM hurry pathway really then this reviewed meeting the any runway so controls any have in the of and that advantage all We I perspective. other special it's and real issues the a is avenue think, some development to great, special don't that eventually. which also But want there not controls. Horizon we're because take from advantage

Operator

with The from question comes Raj you. Denhoy Jefferies. Thank final

line is Your open.

Raj Denhoy

uplift Hi, you'll two, more I curious, you look talk that maintain channel. up the good discussions on maybe that you're Shacey, what you and like the channel you're in And is, expand that one, pharmacies get and channel. you about and to expanding what as us just evening. that whether that premium pharmacy, Wonder ask could intriguing in if that price a I'm tell if if question it's able signing as in

Shacey Petrovic

say for giving sort and price, uplift, pharmacies just the the Raj, are are try. Yeah. nice risk of upfront to have of we not we into it the them. relatively transitioned and a open PDM cost eliminating that We're an value Pod price suffice the for that because

– works time for the testament just in haven't So, the we pharmacy. strong obviously the short such to have We're fact proposition payer and fact we that access period value established the of a the think is that just – a I we we we give I about But we future any position. pricing to how to any good grow. guidance business the of obviously on our there and would think our that expect soon. do time segment expect view kind don't of feel

bottom both line. be expect top more segment We to from attractive a a and

Raj Denhoy

Will lines it that and higher more low anything but the I share as us? isn't of profitable say now given disclosing a to of least the expand you at revenue you're it's for get you your is bigger, something should it guess, you I a be you. I that mix in patients going channel channel same with On quite percentage as is terms that the or imagine meaningful, probably in so in pharmacy,

Shacey Petrovic

Yeah.

around a pharmacy you want color is to be and a give question DASH. DASH it's guys obviously big to think able both we I good piece some because of pharmacy.

percentage are we're on DASH at still So we business of pharmacy patients We're the new what and provide, but metrics you the guys we'll committed where qualitative color the or maybe how some giving quantitative going. in we're to pharmacy. pharmacy percentage looking things can and various certainly like of in discussing

that different you pharmacy, not be we the the provide the we growth that growth So happen certainly out. given if will is model this that revenue that other And piece that quarter And diverges did give of clear, diverge, the going that base would because – color. But color. being or have said we we'll other figure and that to in the where the color. forward pricing we have thing that, will just thing I customer

Operator

that Thank answer the back to conclude now would any I question does closing for today's remarks. you. over Petrovic Shacey call and session. to And like turn

Shacey Petrovic

even thank to all today. Thank an year start we us brighter future. you off for remarkable you and and a up set are We're this XXXX a and for joining great

As to down more the always, excited of I Insulet the momentum living the to the throughout thank be much execution. have strong business people globe, and our very to We with their working the team couldn't across and improve lives want team diabetes. about that's we

forward to and quarter Thank a look have evening. you our great on progress. again next updating you we So

Operator

Ladies conference. today's disconnect. for you This and have Everyone gentlemen, day. program may thank today's you in does and participating a all great conclude

Insulet (PODD) 2 May 192019 Q1 Earnings call transcript